




PORTUGAL

INFARMED, I.P. - National Authority of Medicines and Health Products, IP

Pharmaceutical provision in hospitals

- Most of the in-patient treatments are realised in public hospitals **owned** by the NHS. When waiting list recovery programmes are implemented it's possible to contract out clinical services. These decisions are taken at the regional level.
- The **pharmaceutical provision** in hospitals is organised by **hospital pharmacies**
- Hospital pharmacies serve also **outpatient** in special circumstances defined by law.

Pharmaceutical provision:



Purchasing of medicines in the hospital sector

- Both **centralized** (ACSS-national body) and **decentralized** purchasing (decisions taken individually by the hospitals).
- **Direct negotiations** (hospitals) and **public procurement procedures** launched by ACSS.
- The **Pharmaceutical and Therapeutics Committee** decides which medicines are purchased.
- **Maximum manufacture prices** defined by ACSS (public procurement procedures) and by INFARMED (new medicines). **Published** in each website. **Discounts** are usual but not publicly available.

Financing of medicines in the hospital sector

- **NHS funding**, administrated by ACSS (Central Administration of the Health System) and by regions. **DRG system**, **pay by service** and **own revenues** (hospital admission charges)
- **Patients do not pay** for medicines.
- **National Hospital Pharmaceutical Formulary** with **addendums by hospital** is the list of medicines used in hospitals.
- The **decision making body** is the **Pharmaceutical and Therapeutics Committee** (half physicians and half pharmacists)
- **Addendum criteria:** medical and therapeutic benefit, economic criteria and budget impact, disease and patient specific criteria.

Evaluation and Interface management

- **Consumption, prescription** and **prices** are monitored by **hospital pharmacies** and **hospital administration**. Consumption is monitored at national level by **INFARMED**.
- Since 2007, **evaluation for new medicines** to demonstrate added therapeutic value and economic advantage compared to other products and definition of **maximum price** is performed by **INFARMED**.